NeraCare formed a strategic partnership with SkylineDx, which includes an exclusive co-development and licensing agreement for Immunoprint, a proteomic test used to identify early-stage melanoma patients at high risk of relapse and death.
To access this subscriber-only content please log in or renew your subscription.
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe